Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28707608 | 0.88 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL8334246 | 0.85 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL29778164 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL31300305 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL11376344 | 0.81 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL3977899 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL3978947 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL3978940 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL3976248 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL3976250 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| EP-1620409-B1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| EP-1620409-A1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096780-A1 | QUINOXALINONE-3- ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | KDM4E 1645/4885ALDH1A1 1096/4885SMN1; SMN2 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.